News
VALN
4.430
+0.23%
0.010
Weekly Report: what happened at VALN last week (1111-1115)?
Weekly Report · 5d ago
Kepler Capital Remains a Buy on Valneva (0OB3)
TipRanks · 11/16 01:38
European And US Vaccine Stocks Are Under Pressure - Here's WHy
Benzinga · 11/15 16:21
RFK Jr.'s Nomination to Head Health Department Will Shake Up Vaccine Landscape -- Market Talk
Dow Jones · 11/15 11:22
Vaccine Sector Sell-Off Looks Overdone -- Market Talk
Dow Jones · 11/15 10:34
UK Market Talk Roundup: Shares Losing
Dow Jones · 11/15 10:34
European Vaccine Makers Under Pressure After Trump Picks RFK Jr to Lead Health Department
Dow Jones · 11/15 10:13
Valneva Engages Investors with Promising Vaccine Developments
TipRanks · 11/13 19:49
Weekly Report: what happened at VALN last week (1104-1108)?
Weekly Report · 11/11 09:17
Kepler Capital Remains a Buy on Valneva (0OB3)
TipRanks · 11/09 01:39
Valneva’s Growth Potential Driven by Strong Financials and Strategic Lyme Disease Vaccine Focus
TipRanks · 11/08 11:27
Valneva SE Reports Profitable Nine-Month Performance
TipRanks · 11/08 05:53
Valneva Reports Profitable Quarter Amid Vaccine Launches
TipRanks · 11/07 15:58
Valneva reports nine-month results
Seeking Alpha · 11/07 10:53
BRIEF-Valneva Narrows 2024 Financial Guidance
Reuters · 11/07 06:35
Valneva Narrows Its 2024 Guidance: Now Expects Total Revenues Of €170M-€180M (Prior €170M-€190M), And R&D Investments Between €65M-€75M
Benzinga · 11/07 06:30
BRIEF-Valneva 9M Revenue EUR 116.6 Million
Reuters · 11/07 06:00
VALNEVA SE - LAUNCH OF THE WORLD’S FIRST CHIKUNGUNYA VACCINE IN CANADA AND EUROPE UNDERWAY; FURTHER POTENTIAL APPROVALS EXPECTED IN BRAZIL (Q4 2024) AND THE UK (Q1 2025)
Reuters · 11/07 06:00
Weekly Report: what happened at VALN last week (1028-1101)?
Weekly Report · 11/04 09:17
Weekly Report: what happened at VALN last week (1021-1025)?
Weekly Report · 10/28 09:16
More
Webull provides a variety of real-time VALN stock news. You can receive the latest news about Valneva Se through multiple platforms. This information may help you make smarter investment decisions.
About VALN
Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The Company has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The Company is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.